Abstract
Unlike forward contact tracing, backward contact tracing identifies the source of newly detected cases. This approach is particularly valuable when there is high individual-level variation in the number of secondary transmissions. By using a simple branching process model, we explored the potential of combining backward contact tracing with more conventional forward contact tracing for control of COVID-19.
Competing Interest Statement
AE received a research grant from Taisho Pharmaceutical Co., Ltd.
Funding Statement
AE is financially supported by The Nakajima Foundation and The Alan Turing Institute. QJL is supported by Medical Research Council London Intercollegiate Doctoral Training Program studentship (grant no. MR/N013638/1). GMK is supported by UK Medical Research Council (grant: MR/P014658/1). GFM is supported by NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344). SF [210758/Z/18/Z] and AJK [206250/Z/17/Z] are sponsored by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CMMID COVID-19 Working Group funding statements: Billy J Quilty (NIHR: 16/137/109 & 16/136/46), Matthew Quaife (ERC Starting Grant: 757699, B&MGF: INV-001754), Amy Gimma (Global Challenges Research Fund: ES/P010873/1), Charlie Diamond (NIHR: 16/137/109), Rosalind M Eggo (HDR UK: MR/S003975/1, UK MRC: MC_PC 19065), Kiesha Prem (B&MGF: INV-003174, European Commission: 101003688), W John Edmunds (European Commission: 101003688, UK MRC: MC-PC 19065), Fiona Yueqian Sun (NIHR: 16/137/109), Emily S Nightingale (B&MGF: OPP1183986), James W Rudge (DTRA: HDTRA1-18-1-0051), Simon R Procter (B&MGF: OPP1180644), Rein M G J Houben (ERC Starting Grant: #757699), Sophie R Meakin (Wellcome Trust: 210758/Z/18/Z), Christopher I Jarvis (Global Challenges Research Fund: ES/P010873/1), James D Munday (Wellcome Trust: 210758/Z/18/Z), Kevin van Zandvoort (Elrha R2HC/UK DFID/Wellcome Trust/NIHR, DFID/Wellcome Trust: Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z), Georgia R Gore-Langton (UK MRC: LID DTP MR/N013638/1), Thibaut Jombart (Global Challenges Research Fund: ES/P010873/1, UK Public Health Rapid Support Team, NIHR: Health Protection Research Unit for Modelling Methodology HPRU-2012-10096, UK MRC: MC-PC 19065), Samuel Clifford (Wellcome Trust: 208812/Z/17/Z, UK MRC: MC-PC 19065), Nicholas G. Davies (NIHR: Health Protection Research Unit for Immunisation NIHR200929), Kathleen O'Reilly (B&MGF: OPP1191821), Sam Abbott (Wellcome Trust: 210758/Z/18/Z), Rachel Lowe (Royal Society: Dorothy Hodgkin Fellowship), Megan Auzenbergs (B&MGF: OPP1191821), David Simons (BBSRC LIDP: BB/M009513/1), Nikos I Bosse (Wellcome Trust: 210758/Z/18/Z), Jon C Emery (ERC Starting Grant: #757699), Yang Liu (B&MGF: INV-003174, NIHR: 16/137/109, European Commission: 101003688), Stefan Flasche (Wellcome Trust: 208812/Z/17/Z), Mark Jit (B&MGF: INV-003174; NIHR: 16/137/109, NIHR200929; European Commission: 101003688), Hamish P Gibbs (UK DHSC/UK Aid/NIHR: ITCRZ 03010), Joel Hellewell (Wellcome Trust: 210758/Z/18/Z), Carl A B Pearson(B&MGF: NTD Modelling Consortium OPP1184344, DFID/Wellcome Trust: Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z), Alicia Rosello (NIHR: PR-OD-1017-20002), Timothy W Russell (Wellcome Trust: 206250/Z/17/Z), Oliver Brady (Wellcome Trust: 206471/Z/17/Z), Petra Klepac (Royal Society: RP\EA\180004, European Commission: 101003688)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data collection was involved in this study and the replication code is made publicly available.
